Stock Research for CPRX


Featured Broker: Ally Invest

Get the due diligence for another stock.


CPRX Stock Chart & Research Data

The CPRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CPRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CPRX Due diligence Resources & Stock Charts

The CPRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CPRX Detailed Price Forecast - CNN Money CNN View CPRX Detailed Summary - Google Finance
Yahoo View CPRX Detailed Summary - Yahoo! Finance Zacks View CPRX Stock Research & Analysis -

Stock Analysis

TradeIdeas View CPRX Trends & Analysis - Trade-Ideas Barrons View CPRX Major Holders - Barrons
NASDAQ View CPRX Call Transcripts - NASDAQ Seeking View CPRX Breaking News & Analysis - Seeking Alpha
Spotlight View CPRX Annual Report - OTC Report View CPRX OTC Short Report -
TradeKing View CPRX Fundamentals - TradeKing Charts View CPRX SEC Filings - Bar Chart
WSJ View Historical Prices for CPRX - The WSJ Morningstar View Performance/Total Return for CPRX - Morningstar
MarketWatch View the Analyst Estimates for CPRX - MarketWatch CNBC View the Earnings History for CPRX - CNBC
StockMarketWatch View the CPRX Earnings - StockMarketWatch MacroAxis View CPRX Buy or Sell Recommendations - MacroAxis
Bullish View the CPRX Bullish Patterns - American Bulls Short Pains View CPRX Short Pain Metrics -

Social Media Mentions

StockTwits View CPRX Stock Mentions - StockTwits PennyStocks View CPRX Stock Mentions - PennyStockTweets
Twitter View CPRX Stock Mentions - Twitter Invest Hub View CPRX Investment Forum News - Investor Hub
Yahoo View CPRX Stock Mentions - Yahoo! Message Board Seeking Alpha View CPRX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CPRX - Insider Cow View Insider Transactions for CPRX - Insider Cow
CNBC View CPRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CPRX - OTC Markets
Yahoo View Insider Transactions for CPRX - Yahoo! Finance NASDAQ View Institutional Holdings for CPRX - NASDAQ

Stock Charts

FinViz View CPRX Stock Insight & Charts - StockCharts View CPRX Investment Charts -
BarChart View CPRX Stock Overview & Charts - BarChart Trading View View CPRX User Generated Charts - Trading View

Latest Financial News for CPRX

Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets
Posted on Tuesday December 18, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has signed a Definitive Agreement with Endo International plc's (ENDP) subsidiary, Endo Ventures Limited, for the further development and commercialization of generic Sabril® (vigabatrin) tablets through Endo’s U.S. Generic Pharmaceuticals segment, doing business as Par Pharmaceutical. Pursuant to the agreement, Catalyst will receive an up-front payment,  milestone payments based on achievement of regulatory approvals, and a sharing of defined net profits upon commercialization.

Does Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Have A Volatile Share Price?
Posted on Friday December 14, 2018

If you own shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...

Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments
Posted on Tuesday December 11, 2018

NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
Posted on Monday December 03, 2018

Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases today announced that the company will host a conference call and webcast on December 13, 2018 at 8:30 AM ET to discuss its commercialization plan for Firdapse®, including the cost of therapy. “We look forward to providing the details of the commercial launch plan for Firdapse for the treatment of LEMS, as well as our plan for achieving our stated objective of affordable access to Firdapse for all,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. A webcast replay will be available on the Catalyst website following the call by visiting the Investor page of the company's website at

Stock Market & Investing Books

Enter a stock symbol to view the stock details.